Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-Line

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-Line

Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results

November 8, 2016 4:05 PM EST

DUBLIN, Nov. 8, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2016 and updated financial guidance for 2016.

"We have made substantial progress towards achieving our corporate objectives for 2016, delivering solid top-line growth in our commercial business, investing in broadening our hematology/oncology portfolio with the completion of the Celator acquisition and increasing our investments in R&D," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In the third quarter, we began a rolling NDA submission for Vyxeos for the... More